Quick Heal Technologies Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | IT - Software | Market Cap: ₹830 Cr
Enterprise business is expected to become the dominant revenue contributor soon, overtaking Consumer business, which is structurally declining. Quick Heal Technologies expects steady growth driven by both Consumer and Enterprise segments, with Enterprise set to take a larger revenue share soon (currently around 60-40 split).
From Quick Heal Technologies Ltd's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.
Price
₹141
Market Cap
₹830 Cr
How does Quick Heal Technologies Ltd rank in IT - Software?
Compare Quick Heal Technologies Ltd against every IT - Software company this quarter on revenue, margins and earnings-call signals.
Quick Heal Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹49 Cr, net profit ₹-20 Cr.
Full financials →📊 Revenue & Sales Performance
- →Enterprise business is expected to become the dominant revenue contributor soon, overtaking Consumer business, which is structurally declining.
- →Total Addressable Market (TAM) is projected to increase from INR 1,800 crores to INR 4,000 crores.
- →Enterprise segment expected to contribute around 80% of the INR 4,000 crores TAM; Consumer around 20%.
- →International revenue currently constitutes about 20% of Enterprise revenue.
- →Government segment and international markets targeted for significant growth.
- →New products such as data privacy solutions, threat intelligence platforms, EDR, XDR, STI, and SMAP expected to drive growth.
- →Focus on mid-market and SMB enterprises with 1,000-5,000 endpoints.
- →Continued investments in R&D and sales/marketing to support revenue growth.
- →Consumer business revenue will largely remain stable, aiming to hold market share amid decline.
- →Revenue for Q2 FY ’26 was INR 83.5 crores, showing healthy growth compared to prior periods.
📈 Profitability & Margins
- →Quick Heal Technologies expects steady growth driven by both Consumer and Enterprise segments, with Enterprise set to take a larger revenue share soon (currently around 60-40 split).
- →Enterprise segment, especially mid-market and government sectors, is a key growth lever with increasing traction in products like EDR, XDR, STI, and SMAP.
- →Revenue for Q2 FY26 grew 14% YoY to INR 83.5 crores with an EBITDA margin of around 11%.
- →R&D investments are ongoing but optimized using AI and automation; these expenses are expensed fully and impact EBITDA.
- →Management is cautious on giving specific revenue/EPS guidance but expects that increased enterprise revenue and operational efficiencies will improve margins and profitability.
- →Marketing and sales investments, especially for Enterprise, will continue proportional to revenue growth.
- →Government sector and international markets (20% of revenues) represent significant growth opportunities.
- →Overall, longer-term profitability is expected to improve as Enterprise segment scales and R&D investments yield product benefits.
🏗️ Capital Expenditure Plans
- →The company maintains a strong balance sheet with INR 191 crores cash balance as of 30th September 2025, offering flexibility for investments.
- →They are actively evaluating options for M&A and strategic acquisitions aligned with their vision and roadmap.
- →Investments in R&D remain a priority, with ongoing optimization through AI and automation to sustain product innovation.
- →There are no specific disclosed plans for large current capex, but the firm continues expanding sales and marketing teams, especially for Enterprise growth.
- →The company is focused on leveraging government and international market opportunities, especially through Make in India initiatives, but concrete capex figures or timelines were not detailed.
- →Overall, capital allocation is strategically measured to balance growth in Enterprise and Consumer businesses and continuous R&D investments.
💰 Fundraising & Capital Structure
- →Quick Heal Technologies currently holds a strong balance sheet with INR 191 crores cash and investments as of September 30, 2025.
- →Management has not disclosed any immediate plans for new fundraising through debt or equity.
- →They continuously evaluate options for investments, including potential M&A or acquisitions, and will update investors as appropriate.
- →Any deployment of cash reserves for growth or acquisitions will be aligned with company strategy and board approval.
- →There is no specific mention of raising fresh funds through debt or equity in the current quarter or near future from the provided transcript.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Quick Heal Technologies Ltd's management said in earlier quarters
Others in IT - Software this season
- Sonata Software Ltd (Q2 FY26)
Increasing AI integration and modernization engineering focus to drive growth, with AI order book growing from 8% to 10%. Key concall takeaways from Sonata…
- S A Tech Soft. (Q2 FY26)
Profitability: H1 FY26 saw lower profitability due to 13% rise in employee costs (sales, marketing, AI investment). Key concall takeaways from S A Tech…
- CapitalNumbers (Q2 FY26)
Strategic acquisitions planned, with INR40 crores earmarked for M&A focused on companies in Salesforce, AI, Cloud, or digital engineering domains to expand…
- Delaplex Ltd (Q2 FY26)
. Key concall takeaways from Delaplex Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Quick Heal Technologies Ltd Q2 FY26 results?
Enterprise business is expected to become the dominant revenue contributor soon, overtaking Consumer business, which is structurally declining. Quick Heal Technologies expects steady growth driven by both Consumer and Enterprise segments, with Enterprise set to take a larger revenue share soon (currently around 60-40 split).
What is Quick Heal Technologies Ltd share price analysis?
Quick Heal Technologies Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹830 Cr. Investors should review the full earnings analysis for detailed insights.
Is Quick Heal Technologies Ltd planning capital expenditure?
The company maintains a strong balance sheet with INR 191 crores cash balance as of 30th September 2025, offering flexibility for investments.
Keep Quick Heal Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.